Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2NET 2Gynecologic 2Endocrine 2Sarcoma 1Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 402Rectal Neoplasms 151Colonic Neoplasms 148Pancreatic Neoplasms 113Stomach Neoplasms 106Neoplasm Metastasis 88Neoplasms 74Esophageal Neoplasms 59Small Cell Lung Carcinoma 44Neuroblastoma 42Lung Neoplasms 42Glioblastoma 38Carcinoma, Non-Small-Cell Lung 37Esophageal Squamous Cell Carcinoma 33Brain Neoplasms 33Unspecified Adult Solid Tumor, Protocol Specific 31Glioma 31Breast Neoplasms 28Central Nervous System Neoplasms 27Adenocarcinoma Of Esophagus 27Sarcoma 26Gliosarcoma 22Astrocytoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Adenocarcinoma 18Gastrointestinal Neoplasms 17Oligodendroglioma 16Cholangiocarcinoma 14Recurrence 13

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Irinotecan × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡